You are viewing a preview of...
Combination Decitabine and MPS1 Inhibitor Therapy for KRAS-LKB1 Mutant Lung Cancer
Therapeutic combinations of epigenetic inhibition followed by MSP1 inhibition for KL-mutant lung cancer patients
Background
Lung cancer is the second most common cancer worldwide, and non-small cell lung cancer (NSCLC) accounts for approximately 84% of lung cancers. It is estimated that 25-30% of NSCLC patients present mutations in the KRAS gene, approximately half of whom have deletions or inactivating mutations in the LKB1 gene. KRAS-LKB1 (KL) mutant lung cancers are known to epigenetically silence stimulator of interferon genes (STING), which is activated by a second messenger produced by cyclic guanosine monophosphate (cGAS). Inhibition of the STING pathway suppresses anti-tumor interferon signaling, resulting in T cell exclusion and resistance to programmed cell death (ligand) 1 (PD-L1) blockade. Accordingly, there is a need to gain a deeper understanding of this pathway and develop novel therapeutic strategies
Log in or create a free account to continue reading